NSK-SD Nattokinase in the Treatment of Cardiovascular and Cerebrovascular High Risk Population

Abstract

Abstract: Objective Nattokinase, a fermented soybean extract, has recently been shown to reduce the risk of cardiovascular and cerebrovascular disease. The purpose of this study was to evaluate the efficacy of nattokinase in the cardiovascular and cerebrovascular high-risk population in China. Methods A total of 97 cardiovascular and cerebrovascular high-risk subjects received 8000 FU nattokinase (NSK-SD) daily during the 90-day study period, and blood samples were taken at baseline, on day 30 and day 90, respectively, to detect lipids, clotting, platelet aggregation rate and D-dimer. TCD testing and carotid ultrasound were performed at baseline and day 90. Results All 97 people completed the study with good compliance. After 30 days of nattokinase treatment, plasma viscosity decreased significantly (P<0.05). After taking nattokinase for 90 days, ADP platelet aggregation rate was 300 s, maximum ADP platelet aggregation rate, D-dimer, whole blood low shear viscosity 5/s, whole blood viscosity 50/s and whole blood high shear viscosity 200/s (P<0.05). In addition, whole blood low shear viscosity 1/s decreased significantly after 30 days and 90 days of administration (P<0.05). The improvement rate of patients with different blood flow velocity and flow velocity was 71.4% and 87.5%, respectively. The improvement rates of carotid plaque and media thickening were 46.7% and 42.1%, respectively. Conclusion The intake of nattokinase in the Chinese population was significantly correlated with the improvement of platelet function, D-dimer and whole blood viscosity in the high-risk population of cardiovascular and cerebrovascular diseases, and the effect was more obvious with the extension of time, indicating that nattokinase has a significant effect on the prevention and treatment of cardiovascular and cerebrovascular diseases.

Key words: nattokinase, cardiovascular and cerebrovascular diseases, curative effect, clinical trials

CLC Number:

QIAN Shen-xian, LI Pei-zhang, CHEN Ning, ZHU Ping, AN Qi, ZHAO Xiao-yan, ZHANG Rui-fang, HU Wei-hong, LIU Xiao-ming, WU Bing-nan. NSK-SD Nattokinase in the Treatment of Cardiovascular and Cerebrovascular High Risk Population[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(5): 8-11.

References

[1] GERAGHTY L, FIGTREE G A, SCHUTTE A E, et al.Cardiovascular Disease in Women: From Pathophysiology to Novel and Emerging Risk Factors[J]. Heart Lung Circ,2021,30(1):9-17.
[2] NOZUE M, SHIMAZU T, CHARVAT H, et al.Fermented soy products intake and risk of cardiovascular disease and total cancer incidence: The Japan Public Health Center-based Prospective study[J]. Eur J Clin Nutr,2021, 75(6):954-968.
[3] YAN Z, ZHANG X, LI C, et al.Association between consumption of soy and risk of cardiovascular disease: A meta-analysis of observational studies[J]. Eur J Prev Cardiol,2017,24(7):735-747.
[4] PENG Y, YANG X, ZHANG Y.Microbial fibrinolytic enzymes: an overview of source, production, properties, and thrombolytic activity in vivo[J]. Appl Microbiol Biotechnol,2005,69(2):126-132.
[5] CHEN H, MCGOWAN E M, REN N, et al.Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases[J]. Biomark Insights,2018:13.
[6] KRISHNAMURTHY A, BELUR P D.A novel fibrinolytic serine metalloprotease from the marine Serratia marcescens subsp. sakuensis: Purification and characterization[J]. Int J Biol Macromol,2018,112:110-118.
[7] GUO H, BAN Y H, CHA Y, et al.Comparative anti-thrombotic activity and haemorrhagic adverse effect of nattokinase and tissue-type plasminogen activator[J]. Food Sci Biotechnol,2019,28(5):1535-1542.
[8] HSIA C H, SHEN M C, LIN J S, et al.Nattokinase decreases plasma levels of fibrinogen, factor VⅡ, and factor V Ⅲ in human subjects[J]. Nutr Res, 2009,29(3):190-196.
[9] KUROSAWA Y, NIRENGI S, HOMMA T, et al.A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles[J]. Sci Rep, 2015, 5:11601.
[10] REN N N, CHEN H J, LI Y, et al.A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia[J]. Zhonghua Yi Xue Za Zhi,2017,97(26):2038-2042.
[11] KEZIAH S M, DEVI C S.Fibrinolytic and ACE Inhibitory Activity of Nattokinase Extracted from Bacillus subtilis VITMS 2: A Strain Isolated from Fermented Milk of Vigna unguiculata[J]. Protein J,2021,40(6): 876-890.
[12] JENSEN G S, LENNINGER M, ERO M P, et al.Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial[J]. Integr Blood Press Control,2016,9:95-104.
[13] KIM J Y, GUM S N, PAIK J K, et al.Effects of nattokinase on bloodpressure: a randomized,controlled trial[J]. Hypertens Res,2008,31(8):1583-1588.
[14] BHATT P C, PATHAK S, KUMAR V, et al.Attenuation of neurobehavioral and neurochemical abnormalities in animal model of cognitive deficits of Alzheimer’s disease by fermented soybean nanonutraceutical[J]. Inflammopharmacology,2018,26(1):105-118.

[1]	YE Feng, WANG Tian, FU Dong-mei, CAI Yi-huan, WU Juan, ZENG Yi. Characteristics Analysis of Clinical Trial Registration of Mild Cognitive Impairment based on Chinese Clinical Trial Registry [J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(8): 4-5.
[2]	MIN Jing-jing, DU Lin-dong, NIE Cheng-mei. Observation on Therapeutic Effect of Yishen Fuyang Powder Medicine-Separated Moxibustion on Edema of Nephrotic Syndrome [J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(6): 1-4.
[3]	LIU De-quan, GUO Dan, ZHANG Xiu-rong, YIN Hong, ZHANG Feng, SUN Jian-yi. Efficacy Analysis of Yiqi Huoxue Decoction in the Treatment of Pregnancy-related Uterine Arteriovenous Malformation and the Value of Ultrasonography [J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(6): 1-4.
[4]	YAN Wei, YANG Xiao-lan, YANG Hao, KANG Li-ping, ZHANG Run-mei, LI Wen-juan, HUI Xing-wei. The Effect of Sacubitril Valsartan on Liver and Kidney Function in Patients with Chronic Heart Failure [J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(6): 8-11.
[5]	CHEN Guan-qi, GUO Yong-kun, LIU Wan-qing, MAO Jian-chao, ZHANG Qing-zhu, SHAN Qiao. Analysis of Efficacy and Prognosis of Gamma Knife in the Treatment of Primary Trigeminal Neuralgia in the Elderly [J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(22): 44-48.
[6]	WANG Li. Therapeutic Effect of Niuhuang Shangqing Capsule Combined with Zexie Decoction in the Treatment of Acute Otitis Externa and Its Effect on the Level of Inflammatory Factors [J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(2): 12-15.
[7]	MA Guo-zhang, LI Xiao-lin, LI Nan-nan, LIU Zhi-peng, JIANG Hai-wei. Evaluation of the Therapeutic Effect of Huangqi Guizhi Wuwu Decoction on Peripheral Neuritis after Chemotherapy [J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(19): 22-25.
[8]	TIAN Feng. To Explore the Clinical Efflcacy of Dental Implant Deffcts [J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(18): 168-171.
[9]	WU Chang-zheng, LIU Jing, WANG Li, ZHU Xuan-xuan, MA Li-jing. Clinical Observation on the Treatment of Stroke Related Pneumonia (Phlegm Dampness Accumulated in the Lung Type) Based on Acupuncture Combined with Fuling Decoction [J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(17): 11-14.
[10]	ZHAN Hao, SUN Huan-ying. Analysis of the Efficacy of Budesonide Combined with Fluconazole Irrigation after Allergic Fungal Sinusitis [J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(16): 52-55.
[11]	ZHAO Xuan. Effect of Dengzhan Shengmai Capsule Combined with Perindopril Tert Butylamine on Chronic Heart Failure [J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(12): 8-11.
[12]	WANG Yu. Clinical Analysis of Routine Treatment Combined with Oral Chinese Herbal Decoction in the Treatment of Coronary Heart Disease with Angina Pectoris [J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(10): 29-31.
[13]	LU Yi, WANG Wei, MI Guo-lin, JIAN Jia, ZHENG Yun-shao, LIU Jin-tong. The Efficacy of Repeated Transcranial Magnetic Stimulation in the Treatment of Chronic Insomnia and the Improvement of Cognitive Function and Bad Mood [J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(1): 1-4.
[14]	WANG Xiao-li, CAO Yong-feng, ZHOU Yan. Efficacy of Antiangiogenic Targeted Therapy Combined with Chemotherapy in the Treatment of Advanced Lung Cancer and Its Effect on Carcinoembryonic Antigen,Liver and Kidney Function, Blood Pressure [J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(24): 70-73.
[15]	LIU Hong-shuan, LI Shuo, LIU Qing-quan, YANG Hong. Clinical Observation of Xuanbai Chengqi Supplementing and Reducing Prescription in Improving Sepsis-Associated Acute Lung Injury [J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(20): 1-4.